TEER

MitraClip Transcatheter Edge-to-Edge Repair Clinical Data

Standard-Setting clinical outcomes that never stand still, MitraClip is the only TEER therapy with positive durable outcomes to 5 Years.1-5 With unparalleled clinical outcomes, MitraClip has the highest reported MR reduction6, significant improvements in functional status and quality of life6, and is the only TMV therapy that improved survival and HF hospitalization in Secondary MR.7

A SAFE TREATMENT FOR MITRAL REGURGITATION, A HOPE FOR SELECT PATIENTS

Treating mitral regurgitation (MR) with MitraClip™ therapy can mean an improved quality of life and relief from the symptoms of heart failure. Clinical studies show that intervention with MitraClip transcatheter mitral valve repair (TMVr)—also referred to as TEER (transcatheter edge-to-edge repair)—can safely reduce MR in select patients despite their age or high rate of accompanying serious comorbidities, such as heart failure.8

1.5%

30-DAY
MORTALITY RATE

Evaluating contemporary real-world clinical outcomes in patients treated with MitraClip G4 system.6

96.6%

FREEDOM FROM
DEVICE-RELATED COMPLICATIONS

Within 12 months in heart failure patients with secondary MR9

EXPAND TREATMENT OPTIONS
FOR SELECT HEART FAILURE PATIENTS

Results from the landmark COAPT™ trial established MitraClip therapy’s impact on heart failure patients with clinically significant secondary MR who remained symptomatic despite maximally tolerated guideline-directed medial therapy. By decreasing MR, patients experienced:

  • Improved survival7
  • Reduction in HF hospitalizations7
  • Improved quality of life10
  • At 3 years, MitraClip saves lives7

    * Includes crossover patients (GDMT only patients that were allowed to crossover to MitraClip after 24 months).

    33%

    Relative mortality risk reduction

    .

    7.9

    # Needed to treat to prevent one death*

  • At 3 years, MitraClip reduces HF hospitalizations7


    Includes crossover patients (guideline-directed medical therapy [GDMT] only patients that were allowed to cross over to MitraClip after 24 months).

    51%

    Relative risk reduction in HF hospitalization2

    .

    3.0

    # Needed to treat to prevent 1 HF hospitalization2

  • MitraClip changes the course in patients’ quality of life10

    Note: Kansas City Cardiomyopathy Questionnaire (KCCQ) Minimum for Clinically Important Difference (MCID)=5 points; Large Improvement Defined as ≥20 Points in KCCQ from Baseline; quality of life is assessed only in surviving patients.
    A multicenter, randomized, controlled, parallel-group, open-label trial of transcatheter mitral valve repair (TMVr)* with the MitraClip device was conducted in symptomatic patients with heart failure and moderate-to-severe (grade 3+) or severe (grade 4+) secondary MR. Patients were randomized 1:1 to undergo TMVr with MitraClip and receive GDMT (n=302) or GDMT alone (n=312).8

    *TMVr is now also referred to as TEER (transcatheter edge-to-edge repair)

    2.5x

    More likely to experience a large improvement in quality of life with MitraClip

REAL-WORLD EXPAND STUDIES SHOW UNPARALLED CLINICAL OUTCOMES6

The EXPAND and EXPAND G4 studies were prospective, multi-center, single arm, international, post-market, real-world, observational studies of patients who received MitraClip NTR/XTR and MitraClip G4, respectively.6

  • ECL Adjudicated MR Severity6

    NOTE: Data not from head to head studies. Data differences depicted between these trials may not be directly comparable, statistically significant, or clinically meaningful due to differences in trial protocols, endpoints, and/or patient populations. Data provided for informational purposes only.

    .
     


    MR Reduction to ≤ Mild at 30 days achieved in 90.7% of subjects 95.9% had MR reduction to ≤ Moderate.

  • Statistically significant improvement in heart failure symptoms6,9

    80% of patients with NYHA I/II at 1 year in expand study9


    87% of patients with NYHA I/II at 30 days in expand G4 study6

  • Largest improvement in quality of life reported to date6,9

    EXPAND study 1 year9

    .
     

    21.6 POINTS
    IMPROVEMENT

    in KCCQ-OS at 1 year9

    EXPAND G4 study 30 days6

    .
     

    21 POINTS
    IMPROVEMENT

    in KCCQ-OS at 30 days6

MAT-2201455 v2.0 | Item approved for OUS use only.

Copyright © 2022 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v10.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.